Roche: acquires startup Inflazome
(CercleFinance.com) - The pharmaceutical group Roche has acquired Inflazome, a specialist in inflammatory diseases, the British start-up announced on Monday.
Inflazome's shareholders - created in 2016 by Professor Matt Cooper of the University of Queensland (Australia) and Professor Luke O'Neill of Trinity College, Dublin - will receive 380 million dollars as part of the deal, and any future additional payments related to the progress of its research portfolio.
The company specialises in NLRP3 inflammasomes, human body receptors that play an important role in many diseases caused by a chronic and uncontrolled inflammatory mechanism.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Inflazome's shareholders - created in 2016 by Professor Matt Cooper of the University of Queensland (Australia) and Professor Luke O'Neill of Trinity College, Dublin - will receive 380 million dollars as part of the deal, and any future additional payments related to the progress of its research portfolio.
The company specialises in NLRP3 inflammasomes, human body receptors that play an important role in many diseases caused by a chronic and uncontrolled inflammatory mechanism.
Copyright (c) 2020 CercleFinance.com. All rights reserved.